Loading...

REGN REGENERON PHARMACEUTICALS INC Investments/Divestments 8-K Filing

RGNR

RGN

REGENERON PHARMACEUTICALS INC

(REGN)

2023 8-K

Show Summary

Summary

Financial Statements

Financial Results

Financial Update

Q3 Earnings Report

Q3 2024 Preview

Earnings Reports

Financial Results

Shareholder Vote Results

Financial Results

Financial Results Announcement

Management Appointments

Corporate Update at Healthc...

Financial Results Announcement

Financial Results

Earnings Reports

Amendment to Bylaws and Sha...

Financial Results Announcement

Management Changes

Financial Results for Q1 2023

External Links:

Regeneron Pharmaceuticals expects a $56 million charge in its financial results for Q1 2023 due to an acquired in-process research and development (IPR&D) charge relating to a collaboration and license agreement with Sonoma Biotherapeutics.

AI Assistant

REGENERON PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.